This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Asai, T.
Right arrow Articles by Whiteside, T. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asai, T.
Right arrow Articles by Whiteside, T. L.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, March 2000, p. 145-154, Vol. 7, No. 2
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Evaluation of the Modified ELISPOT Assay for Gamma Interferon Production in Cancer Patients Receiving Antitumor Vaccines

Tadao Asai,1 Walter J. Storkus,1,2,3 and Theresa L. Whiteside1,2,*

University of Pittsburgh Cancer Institute1 and Departments of Pathology2 and Surgery,3 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213

Received 28 June 1999/Returned for modification 25 August 1999/Accepted 5 October 1999

Frequencies of vaccine-responsive T-lymphocyte precursors in peripheral blood mononuclear cells (PBMC) prior to and after administration of peptide-based vaccines in patients with cancer can be measured by limiting-dilution assays (LDA) or by ELISPOT assays. We have used a modified version of the ELISPOT assay to monitor changes in the frequency of gamma interferon (IFN-gamma )-producing T cells in a population of lymphocytes responding to a relevant peptide or a nonspecific stimulator, such as phorbol myristate acetate-ionomycin. Prior to its use for monitoring of patient samples, the assay was validated and found to be comparable to the LDA performed in parallel, using tumor-reactive cytolytic T-lymphocyte (CTL) lines. The sensitivity of the ELISPOT assay was found to be 1/100,000 cells, with an interassay coefficient of variation of 15%, indicating that it could be reliably used for monitoring of changes in the frequency of IFN-gamma -secreting responder cells in noncultured or cultured lymphocyte populations. To establish that the assay is able to detect the T-cell precursor cells responsive to the vaccine, we used CD8+ T-cell populations positively selected from PBMC of HLA-A2+ patients with metastatic melanoma, who were treated with dendritic cell-based vaccines containing gp100, MELAN-A/MART-1, tyrosinase, and influenza virus matrix peptides. The frequency of peptide-specific responder T cells ranged from 0 to 1/2,600 before vaccination and increased by at least 1 log unit after vaccination in two patients, one of whom had a clinical response to the vaccine. However, no increases in the frequency of peptide-responsive T cells were observed in noncultured PBMC or PBMC cultured in the presence of the relevant peptides after the melanoma patients enrolled in another trial were treated with the intramuscular peptide vaccine plus MF59 adjuvant. Thus, while the ELISPOT assay was found to be readily applicable to assessments of frequencies of CTL precursors of established CTL lines and ex vivo-amplified PBMC, its usefulness for monitoring of fresh PBMC in patients with cancer was limited. In many of these patients antitumor effector T cells are present at frequencies of lower than 1/100,000 in the peripheral circulation. Serial monitoring of such patients may require prior ex vivo amplification of specific precursor cells.

* Corresponding author. Mailing address: University of Pittsburgh Cancer Institute, W1041 BST, 211 Lothrop St., Pittsburgh, PA 15213-2582. Phone: (412) 624-0096. Fax: (412) 624-0264. E-mail: whitesidetl{at}msx.upmc.edu.

Clinical and Diagnostic Laboratory Immunology, March 2000, p. 145-154, Vol. 7, No. 2
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Comin-Anduix, B., Gualberto, A., Glaspy, J. A., Seja, E., Ontiveros, M., Reardon, D. L., Renteria, R., Englahner, B., Economou, J. S., Gomez-Navarro, J., Ribas, A. (2006). Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays. Clin. Cancer Res. 12: 107-116 [Abstract] [Full Text]  
  • Kronfeld, K., Hochleitner, E., Mendler, S., Goldschmidt, J., Lichtenfels, R., Lottspeich, F., Abken, H., Seliger, B. (2005). B7/CD28 Costimulation of T Cells Induces a Distinct Proteome Pattern. Mol. Cell. Proteomics 4: 1876-1887 [Abstract] [Full Text]  
  • de Bono, J. S., Rha, S. Y., Stephenson, J., Schultes, B. C., Monroe, P., Eckhardt, G. S., Hammond, L. A., Whiteside, T. L., Nicodemus, C. F., Cermak, J. M., Rowinsky, E. K., Tolcher, A. W. (2004). Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol 15: 1825-1833 [Abstract] [Full Text]  
  • Whiteside, T. L., Stanson, J., Shurin, M. R., Ferrone, S. (2004). Antigen-Processing Machinery in Human Dendritic Cells: Up-Regulation by Maturation and Down-Regulation by Tumor Cells. J. Immunol. 173: 1526-1534 [Abstract] [Full Text]  
  • Lou, Q., Kelleher, R. J. Jr, Sette, A., Loyall, J., Southwood, S., Bankert, R. B., Bernstein, S. H. (2004). Germ line tumor-associated immunoglobulin VH region peptides provoke a tumor-specific immune response without altering the response potential of normal B cells. Blood 104: 752-759 [Abstract] [Full Text]  
  • Kaufman, H. L., Wang, W., Manola, J., DiPaola, R. S., Ko, Y.-J., Sweeney, C., Whiteside, T. L., Schlom, J., Wilding, G., Weiner, L. M. (2004). Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group. JCO 22: 2122-2132 [Abstract] [Full Text]  
  • Laport, G. G., Levine, B. L., Stadtmauer, E. A., Schuster, S. J., Luger, S. M., Grupp, S., Bunin, N., Strobl, F. J., Cotte, J., Zheng, Z., Gregson, B., Rivers, P., Vonderheide, R. H., Liebowitz, D. N., Porter, D. L., June, C. H. (2003). Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 102: 2004-2013 [Abstract] [Full Text]  
  • Admon, A., Barnea, E., Ziv, T. (2003). Tumor Antigens and Proteomics from the Point of View of the Major Histocompatibility Complex Peptides. Mol. Cell. Proteomics 2: 388-398 [Abstract] [Full Text]  
  • Whiteside, T. L., Zhao, Y., Tsukishiro, T., Elder, E. M., Gooding, W., Baar, J. (2003). Enzyme-linked Immunospot, Cytokine Flow Cytometry, and Tetramers in the Detection of T-Cell Responses to a Dendritic Cell-based Multipeptide Vaccine in Patients with Melanoma. Clin. Cancer Res. 9: 641-649 [Abstract] [Full Text]  
  • Whiteside, T. L., Gambotto, A., Albers, A., Stanson, J., Cohen, E. P. (2002). Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses exvivo. Proc. Natl. Acad. Sci. USA 99: 9415-9420 [Abstract] [Full Text]  
  • Smith, J. G., Liu, X., Kaufhold, R. M., Clair, J., Caulfield, M. J. (2001). Development and Validation of a Gamma Interferon ELISPOT Assay for Quantitation of Cellular Immune Responses to Varicella-Zoster Virus. CVI 8: 871-879 [Abstract] [Full Text]  
  • Whiteside, T. L. (2000). Monitoring of Antigen-Specific Cytolytic T Lymphocytes in Cancer Patients Receiving Immunotherapy. CVI 7: 327-332 [Full Text]  
  • Gajewski, T. F. (2000). Monitoring Specific T-Cell Responses to Melanoma Vaccines: ELISPOT, Tetramers, and Beyond. CVI 7: 141-144 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»